25-04-2025
Bactiguard Holding AB (OSTO:BACTI B) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
Release Date: April 24, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Bactiguard Holding AB (OSTO:BACTI B) reported continued profitability and revenue growth, with an EBITA of SEK9.4 million and revenues of SEK62.7 million, marking a 7% increase compared to Q1 last year.
The company has seen a significant increase in license revenues, primarily due to a strengthened collaboration with medtech company BD.
Revenues from the wound management portfolio increased by more than 50%, driven by sales of the Hydrason Aqua line of products.
Bactiguard Holding AB has maintained positive financial development for four consecutive quarters, demonstrating consistent delivery on its profitability promises.
The company has set ambitious strategic and financial targets for 2030, including achieving revenues of at least SEK600 million and EBITA of at least SEK200 million, supported by more than 10 application areas in exclusivity or license partnerships.
Despite the positive financial results, Bactiguard Holding AB reported a net loss of SEK4.7 million for the period.
The company's cash position decreased to SEK46.8 million at the end of Q1, primarily due to a planned repayment of SEK51 million on loans.
There is substantial US dollar exposure in the license business, and a weaker US dollar could negatively affect results.
Sales to the licensed partner in China, Well Lead, tend to be volatile and are not expected to show significant growth this year.
The cost of raw materials increased, impacting the cost of goods sold, particularly related to sales in China.
Warning! GuruFocus has detected 2 Warning Signs with OSTO:BACTI B.
Q: Could you elaborate on the significant increase in partner revenues, particularly regarding sales from China, and explain the rise in raw material costs? A: Yes, we have seen growth in sales to our licensed partner in China, Well Lead, but these revenues tend to be lumpy. We don't expect significant growth from China this year. The increase in raw material costs is mainly related to sales to China, and the absence of exclusivity revenues also affects margins. - Patrick Buck, CFO
Q: Regarding the high wound management sales, should this be seen as a new level, or were there large orders for Hydrason Aqua this quarter? A: The growth in wound management sales was higher than expected, driven by both existing and new markets. While we expect continued double-digit growth, we don't anticipate a 50% increase every quarter. The first quarter is usually a low month for wound management sales. - Patrick Buck, CFO
Q: Can you comment on the OpEx cost control this quarter and whether this level is expected to continue? A: We reported lower OpEx this quarter, and our rolling 12-month OpEx is now at a 200 million level. While we will continue to invest in our organization, we will maintain cost control and focus on growing profitability. - Patrick Buck, CFO
Q: How is the work progressing to find new partners in related therapeutic areas, and has there been any change in the level of interest? A: The level of activity in business development has increased significantly over the past 12 to 18 months. We see increasing interest and more activity in early feasibility work with partners. However, moving from early feasibility to announced partnerships will take time. - Christine, CEO
Q: What is the outlook for the BD partnership and its impact on license revenue growth? A: The BD collaboration is a solid backbone for driving license revenue growth. It is a model partnership with aligned incentives, mutual trust, and respect, enabling win-win outcomes. We continue to work on market registrations for new markets. - Christine, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
